Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 10,623 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Human Immunodeficiency Virus
Interventions: Client-Centered Representative Payee; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 100 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Birmingham, Alabama • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Solid Tumors
Interventions: INCB161734, Placebo, Investigator's choice of chemotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 69
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 55 more

Conditions: Stress Disorders, Post-Traumatic
Interventions: Trauma-Focused CBT, Child-Centered Therapy; Behavioral
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 8 Years to 14 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 3
States / cities: Stratford, New Jersey • Pittsburgh, Pennsylvania

Conditions: Optic Neuropathy, Ischemic
Interventions: No intervention; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 69
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 57 more

Conditions: Nocturia, Insomnia
Interventions: Brief behavioral treatment of insomnia, MI, Control, BBTI+MI; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Abdominal Aortic Aneurysms, Aorto-iliac Aneurysms, Juxtarenal Aneurysms
Interventions: Zenith® Fenestrated AAA Endovascular Graft; Device
Lead sponsor: Cook Group Incorporated; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 15
States / cities: San Francisco, California • Gainesville, Florida • Indianapolis, Indiana + 11 more

Conditions: Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
Interventions: Teplizumab, Placebo infusion; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 45 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 17
States / cities: San Francisco, California • Stanford, California • Denver, Colorado + 13 more

Conditions: Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 127
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 124 more

Conditions: Solid Tumor, Adult
Interventions: CX-801, pembrolizumab; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Englewood, Colorado • Pittsburgh, Pennsylvania + 2 more

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: amifostine trihydrate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 74
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 67 more

Conditions: Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Interventions: Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 19
States / cities: Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more

Conditions: Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration; Drug · Procedure · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 338
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more

Conditions: Systemic Lupus Erythematosus
Interventions: Ortho-Novum 777; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 15
States / cities: Los Angeles, California • Chicago, Illinois • Shreveport, Louisiana + 11 more

Conditions: Brain and Central Nervous System Tumors
Interventions: laromustine; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 21 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 10
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Conditions: Spinal Cord Injury, Neurogenic Bladder (NB), Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, Spina Bifida, Urinary Tract Infection(UTI)
Interventions: Gentamicin, Lactobacillus Rhamnosus GG; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Pittsburgh, Pennsylvania

Conditions: Brain Diseases, Spinal Cord Diseases
Interventions: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), OptiMARK~0.1 mmol/kg BW; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more

Conditions: Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
Interventions: 5 mg Serlopitant Tablets; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 46
States / cities: Birmingham, Alabama • Fremont, California • North Hollywood, California + 42 more

Conditions: Subdural Hematoma, Traumatic
Interventions: Temperature management Zoll Intravascular Temperature Management device; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 22 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 5
States / cities: Miami, Florida • Atlanta, Georgia • Cincinnati, Ohio + 2 more

Conditions: Malignant Melanoma
Interventions: MEDI-522; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Stage III Colorectal Cancer
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non-small Cell Lung Cancer
Interventions: seliciclib, placebo; Drug
Lead sponsor: Cyclacel Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 20
States / cities: Tucson, Arizona • Fountain Valley, California • New Port Richey, Florida + 16 more

Conditions: PI3K Pathway Activated Tumors
Interventions: BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 59
States / cities: Phoenix, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 52 more

Conditions: Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Reconstruction, Joint Instability
Interventions: Anterior cruciate ligament reconstruction (ACLR), Lateral extra-articular tenodesis (LET); Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 14 Years to 25 Years
Enrollment: 1,272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 14
States / cities: Redwood City, California • San Francisco, California • Orlando, Florida + 11 more

Search by objective public record fields.

Impact of Representative Payee Services on ART Adherence Among Marginalized People Living With HIV/AIDS

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Treatment of Post-Traumatic Stress Disorder (PTSD) in Sexually Abused Children

A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness

Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Continued Access Study

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

First In Human Study of CX-801 in Advanced Solid Tumors

Identification of Carotid Vasa Vasorum and Correlation With Acute Coronary Events

Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Safety of Estrogens in Lupus: Birth Control Pills

VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors

Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

To Study the Effect of Early Cooling in Acute Subdural Hematoma Patients

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

Use of ctDNA for Monitoring of Stage III Colorectal Cancer

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

BKM120 for Patients With PI3K-activated Tumors

STABILITY 2: Anterior Cruciate Ligament Reconstruction +/- Lateral Tenodesis With Patellar vs Quad Tendon